Trisenox disrupts MDM2-DAXX-HAUSP complex and activates p53, cell cycle regulation and apoptosis in acute leukemia cells

Trisenox (TX) has been used in the treatment of both de novo and relapsed acute promyelocytic leukemia (APL) patients. Using in vitro APL cell lines model in this research, we report on a new target of TX action through disruption of MDM2-DAXX-HAUSP complex, degradation of MDM2, and activation of p5...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Sanjay, Brown, Andrea, Tchounwou, Paul B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145703/
https://www.ncbi.nlm.nih.gov/pubmed/30237857
http://dx.doi.org/10.18632/oncotarget.26025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145703/
https://www.ncbi.nlm.nih.gov/pubmed/30237857
http://dx.doi.org/10.18632/oncotarget.26025

Ejemplares similares